ERBB2 and metastatic neoplasm: A retrospective analysis of outcomes in 4033 patients from 2008 to 2014 found that HER2-positive metastatic disease was associated with longer median OS compared to HER2-negative disease: HER2+/HR+ disease 18.9 months, HER2+/HR− disease 13.1 months, HER2−/HR+ 7.1 months, and TNBC 4.4 months [54].